Best Peptides for Muscle Growth: A Research Comparison

Research protocols investigating growth-hormone pharmacology and lean-mass endpoints draw on two distinct compound classes: GHRH analogues (Tesamorelin, CJC-1295) and growth hormone secretagogues, or GHS (Ipamorelin, Hexarelin). The two classes drive GH release through separate receptor pathways and are frequently stacked because the pharmacology is synergistic. This article compares the four compounds most commonly used in research protocols in this area.

The Sigalos and Pastuszak 2018 review in Sex Med Rev is the best external framing for the class landscape ¹: it covers mechanism, safety profile, and dosing considerations across both GHRH analogues and GHS in one coherent document. Researchers new to the area should read it before selecting compounds.

Comparison at a glance

How to choose between them

The first question is whether the research protocol needs pulsatile or sustained GH elevation.

For pulsatile GH work (closer to the physiological daily rhythm), combine a GHS with a GHRH analogue on an acute schedule. The canonical stack is Ipamorelin + CJC-1295. Both produce GH pulses when administered together, and both are selective enough to allow chronic dosing without significant off-target effects.

For sustained baseline GH and IGF-1 elevation (less physiological, but useful for research questions about chronic GH exposure), CJC-1295 with DAC alone is the choice. Albumin binding stretches the half-life to ~8 days and produces a flatter GH profile.

For GHRH-pathway pharmacology research specifically, Tesamorelin is the FDA-approved reference standard, with the Falutz 2007 NEJM trial as the definitive clinical endpoint ⁴.

For acute GH-response research (single-dose pharmacology, GH-ceiling studies), Hexarelin produces the strongest peak but with a cortisol and prolactin cost that limits chronic use.

Ipamorelin

Ipamorelin is the selective growth hormone secretagogue. Raun and colleagues’ 1998 Eur J Endocrinol paper established the selectivity profile: GH release driven by GHS-R1a (ghrelin receptor) binding, without the cortisol, prolactin, or ACTH elevation that earlier GHS compounds produced ². That selectivity is the reason Ipamorelin is the default GHS in contemporary research protocols.

Where the literature stands: the 1998 Raun paper remains the reference for the selectivity claim. Subsequent research has replicated the profile across species and dose ranges.

Why a researcher picks Ipamorelin: chronic protocols (weeks to months) where cortisol and prolactin stability matter. Pairs naturally with CJC-1295 on an acute schedule: Ipamorelin drives GH release through the ghrelin pathway, CJC-1295 primes the GHRH pathway, and the combined pulse exceeds what either produces alone.

CJC-1295 (DAC)

CJC-1295 is a modified GHRH(1-29) analogue with a drug affinity complex (DAC) that covalently binds to circulating albumin. The albumin binding extends the half-life to approximately 8 days and shifts the pharmacology from pulsatile stimulation toward sustained elevation of baseline GH and IGF-1.

Where the literature stands: Teichman and colleagues’ 2006 J Clin Endocrinol Metab paper is the foundational dosing reference ³. They documented prolonged GH and IGF-1 elevation with weekly SC CJC-1295 across a dose range.

Why a researcher picks CJC-1295 (DAC): research protocols that require sustained GH or IGF-1 elevation without daily injection burden. Once-weekly dosing is the standard regimen. Note that the non-DAC variant (often called mod-GRF 1-29) has a much shorter half-life (~30 minutes) and is used differently; when literature or protocols reference “CJC-1295” without specifying, they usually mean the DAC variant.

Tesamorelin

Tesamorelin is a 44-amino-acid stabilised GHRH analogue and the only FDA-approved compound in this article (for HIV-associated visceral fat accumulation). The Falutz 2007 NEJM trial in HIV-infected patients established the clinical endpoint: selective visceral adipose tissue reduction without meaningful change in subcutaneous fat, achieved through GHRH-pathway-driven GH pulsatility ⁴.

Where the literature stands: the Falutz 2007 paper is the definitive clinical reference, and subsequent work (Stanley 2014 JAMA on VAT and liver fat) extended the metabolic findings. Outside the HIV indication, Tesamorelin is used in research protocols focused on the pituitary GHRH receptor itself.

Why a researcher picks Tesamorelin: research questions specifically about GHRH pulsatility, HIV-lipodystrophy research contexts, or protocols that benefit from the most-validated GHRH analogue in the literature. Daily SC dosing (evening, to align with endogenous GH release) is the standard.

Hexarelin

Hexarelin is a synthetic hexapeptide GHS that activates both the ghrelin receptor (GHS-R1a) and the CD36 scavenger receptor. It produces a stronger acute GH response than Ipamorelin, but also elevates cortisol, prolactin, and ACTH to a meaningfully greater degree. Chronic dosing shows GH-response attenuation (tachyphylaxis), which limits its usefulness in protocols running longer than a few weeks.

Where the literature stands: most Hexarelin research is from the 1990s and early 2000s, primarily from Italian endocrinology groups. It retains niche research utility for acute GH-response work and for GH-ceiling studies where a strong single-dose response is the research endpoint.

Why a researcher picks Hexarelin: short-protocol acute-response research, or comparative pharmacology across the GHS class. For chronic muscle-research protocols, Ipamorelin is the better choice.

Stacking considerations

The canonical GH-axis research stack is Ipamorelin + CJC-1295 (DAC). Rationale:

1. Complementary receptors. Ipamorelin drives GH release through the ghrelin receptor (GHS-R1a); CJC-1295 primes the parallel GHRH receptor pathway on the same somatotrophs. Combined activation produces a larger GH pulse than either compound alone.
2. Complementary schedules. Ipamorelin is short-half-life and dosed 2–3 times daily. CJC-1295 DAC is long-half-life and dosed 1–2 times weekly. Protocols do not have to reconcile injection volumes or site conflicts.
3. Tolerability. Both compounds are selective enough to support chronic dosing without clinically meaningful cortisol or prolactin elevation at research doses.

Tesamorelin + Ipamorelin is a less common alternative, used in research specifically focused on GHRH-pathway pharmacology.

Hexarelin is rarely stacked chronically; its tachyphylaxis profile makes it a short-protocol tool.

Where to order

All four compounds are supplied by Thailand Peptides from the Bangkok research desk. Same-week Thailand delivery, lab reports on request, WhatsApp ordering.

• Buy Ipamorelin: 5 mg vials, ≥98% HPLC purity
• Buy CJC-1295: 2 mg vials (DAC variant), ≥98% HPLC purity
• Buy Tesamorelin: 2 mg vials, ≥98% HPLC purity
• Buy Hexarelin: 5 mg vials, ≥98% HPLC purity

The Ipamorelin + CJC-1295 combination is the most-ordered stack in this category. Research desk will confirm bundled pricing in chat.